RxDoctor Payments Data

Fadi Matar, MD

Interventional Cardiology · Tampa, FLNPI 1679512479

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $25,267 of the $33,493 with a category attached, or 75.4%. 20 manufacturers reported payments, led by GE HealthCare at 37.5% of the total.

$33,493in general payments, 2019–2025

Across 226 payments — averaging $148.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$13K
  • Siemens Medical Solutions USA, Inc.$9K
  • Abbott$4K
  • Medtronic$3K
  • Edwards Lifesciences$2K
  • Ancora Heart, Inc.$2K
  • plus $2K from 14 others
$414,753in research payments, 2019–2025

Across 121 payments — averaging $3427.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cvrx, Inc.$272K
  • Gentuity, LLC$77K
  • Abbott$66K

What the payments were for

  • Grants$550%
  • Travel & lodging$25,26775%
  • Food & beverage$8,13824%
  • Entertainment$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,493 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$171,700
Medicare patients
434
Services billed
1,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol90$113,355
EntrestoSacubitril/Valsartan78$108,083
EliquisApixaban73$85,789
Repatha SureclickEvolocumab42$37,987
XareltoRivaroxaban20$17,287
Praluent PenAlirocumab13$9,330
Ranolazine ErRanolazine45$5,171
Metoprolol Succinate63$1,308
Rosuvastatin Calcium86$1,062
Ezetimibe28$1,023
Spironolactone48$842
Atorvastatin Calcium131$828
ClopidogrelClopidogrel Bisulfate60$774
Isosorbide Mononitrate ErIsosorbide Mononitrate33$607
Losartan Potassium41$484

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →